Latham & Watkins advised ShapeTX on the deal. Otsuka Pharmaceutical Co., Ltd. and ShapeTX announced a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
You must be a Standard 1 Year member to access this content.
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Erasca on the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented CytomX in the transaction. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) have announced a collaboration and licensing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Orbital Therapeutics on the deal. Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
